Journal editors question sale of diet pill Meridia

Sep 01, 2010 By STEPHANIE NANO , Associated Press Writer

(AP) -- Editors of a top medical journal are questioning whether the diet pill Meridia should stay on the market even if it's restricted to people without heart disease.

A new study shows the appetite suppressant raises the risk of and stroke in people with heart problems.

The strongly worded editorial in Thursday's comes two weeks before government advisers review the prescription drug.

The weight-loss pill has already been pulled in Europe and U.S. drug regulators have added stronger warnings to the label.

The maker of the diet pill, Abbott Laboratories, says it's still appropriate for obese people who don't have and who can't lose weight through diet and exercise.

Explore further: FDA approves raplixa to help control surgical bleeding

0 shares

Related Stories

Experimental diet pill shows promise, little risk

Jul 14, 2010

(AP) -- An experimental diet pill helped about half the people who tried it lose some weight and keep it off a year later, without the heart problems that some earlier drugs caused, a study found.

Health Canada warns against Meridia

Oct 16, 2007

Health Canada issued a warning for doctors not to prescribe the weight loss drug Meridia to people who may be at risk of serious heart-related side effects.

FDA to review first of 3 new weight loss drugs

Jul 12, 2010

(AP) -- Dieters, doctors and investors get their first extensive look at the first of a trio of new weight loss drugs this week. The hope is that the new drugs can succeed where many others have failed: delivering significant ...

FDA panel rejects experimental weight loss pill

Jul 15, 2010

(AP) -- A panel of federal health experts dealt a surprising setback Thursday to a highly anticipated anti-obesity pill from Vivus Inc., saying the drug's side effects outweigh its ability to help patients lose weight.

Pill claims weight loss with no diet

Oct 08, 2007

Akavar 20/50, a pill produced in Salt Lake City, has become the most recent product to advertise weight loss with no diet or exercise.

Recommended for you

Solid, heat-resistant vaccine to ease immunisation processes

Apr 30, 2015

EU researchers have set out to substitute liquid and freeze-dried vaccines for new, solid state candidates. If successful, the research will enable the large scale production of new virosome-based vaccines with increased ...

Screening for bacteriuria in pregnant women: Benefit unclear

Apr 30, 2015

Due to a lack of suitable studies, no conclusions can be drawn on the patient-relevant benefit or harm of screening for asymptomatic bacteriuria (ASB) in pregnant women. The benefit of antibiotic treatment of ASB following ...

First generic Abilify approved

Apr 30, 2015

(HealthDay)—The first generic versions of the atypical antipsychotic drug Abilify (aripiprazole) have been approved by the U.S. Food and Drug Administration to treat schizophrenia or bipolar disorder.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.